Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Microvessel Density And Status Of P53 Protein As Potential Prognostic Factors For Adjuvant Anthracycline Chemotherapy In Retrospective Analysis Of Early Breast Cancer Patients Group

B. Biesaga, J. Niemiec, M. Ziobro
Published 2012 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
A considerable subgroup of patients with early breast cancer does not address benefits of anthracycline based chemotherapy. The aim of this retrospective study was to investigate the effect of microvessel density (MVD) and status of p53 protein on 5-year disease free survival (DFS) in the group of breast cancer patients treated with anthracyclines in adjuvant setting. Correlations between MVD, p53 status and other clinicopathological parameters were also assessed. MVD and p53 status were analyzed immunohistochemically in the group of 172 women with breast cancer in clinical stage T1-2, N1-N2, M0. There were 123 tumors (71.5 %) with lower MVD (≤214.8 microvesells/mm2) and 49 (28.5 %) with higher MVD (>214.8 microvesells/mm2). The proportion of higher MVD tumors significantly increased in N2 (P = 0.000) and in estrogen (P = 0.046) or progesterone receptors (P = 0.029) negative tumors. p53 positivity was indicated in 50 cancers (29.1 %) and was significantly associated with higher grade (P = 0.000), steroid receptors negativity (P = 0.000), cytokeratin5/6 positivity (P = 0.026), topoisomerase IIα overexpression (P = 0.005) and higher proliferation rate (P = 0.001). In univariate analysis, higher MVD (P = 0.016) and p53 negativity (P = 0.023) were significantly related with longer DFS (median follow-up 36 months). In multivariate Cox regression analysis MVD was independently associated with DFS. These data suggest that higher MVD is favourable prognostic factors for early advanced breast cancer patients after adjuvant anthracycline based chemotherapy.
This paper references
10.1023/A:1006112927565
Association of angiogenesis and poor prognosis in node‐positive patients receiving anthracycline‐based adjuvant chemotherapy
P. Viens (2004)
10.1126/SCIENCE.7973635
p53 status and the efficacy of cancer therapy in vivo.
S. Lowe (1994)
10.1002/SIM.5511
Contrasting treatment‐specific survival using double‐robust estimators
K. Kim (2012)
10.1016/0959-8049(93)90008-4
Vascular density and the response of breast carcinomas to mastectomy and adjuvant chemotherapy.
E. Protopapa (1993)
10.1007/978-1-4612-4380-9_24
Introduction to Kaplan and Meier (1958) Nonparametric Estimation from Incomplete Observations
N. Breslow (1992)
10.3892/ijo.23.5.1431
p53-deficient cells display increased sensitivity to anthracyclines after loss of the catalytic subunit of the DNA-dependent protein kinase.
A. Fedier (2003)
10.1007/s11095-006-9075-5
Heterogeneity of Breast Cancer among Patients and Implications for Patient Selection for Adjuvant Chemotherapy
F. André (2006)
10.1016/J.CARDIORES.2006.04.015
Redox signaling in angiogenesis: role of NADPH oxidase.
M. Ushio-Fukai (2006)
10.1038/bjc.1997.484
Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer.
E. Niskanen (1997)
10.1023/A:1025755717912
Evaluation of the Prognostic Role of Vascular Endothelial Growth Factor and Microvessel Density in Stages I and II Breast Cancer Patients
V. Ludovini (2004)
10.1158/1078-0432.CCR-03-0054
Predicting Early Failure after Adjuvant Chemotherapy in High-Risk Breast Cancer Patients with Extensive Lymph Node Involvement
I. F. Faneyte (2004)
10.1016/S0140-6736(05)66544-0
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group (2005)
10.1093/JNCI/88.23.1764
Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer.
R. Heimann (1996)
Prognostic significance of microvessel density in breast cancer of Thai women.
S. Kanjanapanjapol (2007)
The prognostic evaluation of tumor angiogenesis in invasive breast carcinoma
E. Ioachim (2002)
10.1016/S0140-6736(05)66544-0
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
O. Abe (2005)
10.1016/j.canlet.2008.10.049
p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1/VEGF-A pathway.
N. Khromova (2009)
10.1371/journal.pone.0003062
CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer
R. Chrisanthar (2008)
10.1016/j.breast.2011.03.002
Prognostic potential of topoisomerase IIα and HER2 in a retrospective analysis of early advanced breast cancer patients treated with adjuvant anthracycline chemotherapy.
B. Biesaga (2011)
10.1371/journal.pone.0019249
Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel
R. Chrisanthar (2011)
10.1093/ANNONC/MDL147
Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
V. Malamou-Mitsi (2006)
10.1007/s10549-011-1377-6
Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial
O. Gluz (2011)
Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
S. Geisler (2001)
10.1200/JCO.20.3.732
Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869.
A. J. Guidi (2002)
10.1016/S1359-6349(08)71775-0
Biological prognostic factors for disease free survival in breast cancer patients treated with adjuvant anthracycline chemotherapy
B. Biesaga (2008)
What's going on 乳癌 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Lancet. 2005; 365: 1687-717. PMID: 15894097.--早期乳癌に対する化学療法・内分泌療法が乳癌再発・15年生存率に及
青儀 健二郎 (2006)
10.1158/0008-5472.CAN-03-1957
Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis.
B. Uzzan (2004)
10.1093/JNCI/90.18.1346
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.
A. Thor (1998)
10.1097/00000421-200012000-00002
Angiogenesis and p53 Protein Expression in Breast Cancer: Prognostic Roles and Interrelationships
F. Tas (2000)
10.1038/onc.2011.72
Anthracyclines induce the accumulation of mutant p53 through E2F1-dependent and -independent mechanisms
Michael Bug (2011)
10.1007/978-1-4612-4380-9_25
Nonparametric Estimation from Incomplete Observations
E. L. Kaplan (1958)
10.1200/JCO.1994.12.3.454
Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma.
G. Gasparini (1994)
10.1007/PL00008478
Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy
M. Mottolese (2000)
10.1056/NEJM199101033240101
Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma.
N. Weidner (1991)
10.1038/sj.bjc.6603875
Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy
Y. Nieto (2007)
10.1111/j.1365-2559.2004.01848.x
Microvessel density compared with the Chalkley count in a prognostic study of angiogenesis in breast cancer patients
S. Hansen (2004)
10.1038/NG0593-42
Gain of function mutations in p53
D. Dittmer (1993)
10.1053/j.seminoncol.2008.02.010
Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired.
A. Chien (2008)
10.1038/bjc.1997.506
Examining the technique of angiogenesis assessment in invasive breast cancer.
L. Martin (1997)
10.1078/0344-0338-00177
Prognostic importance of tumor angiogenesis in breast carcinoma with adjuvant chemotherapy.
N. Gunel (2002)
10.1007/s12253-011-9387-6
Angiogenesis Markers Quantification in Breast Cancer and Their Correlation with Clinicopathological Prognostic Variables
J. Rykala (2011)
-deficient cells display increased sensitivity to anthracyclines after loss of the catalytic subunit of the DNA-dependent protein kinase
A Fedier (2003)



This paper is referenced by
10.7314/APJCP.2013.14.12.7651
Angiogenesis markers in breast cancer--potentially useful tools for priority setting of anti-angiogenic agents.
Elahe Keyhani (2013)
10.5433/1679-0359.2019V40N5P1849
Microvessel density assessment in canine mammary carcinomas as a predictive factor for metronomic chemotherapy
Analy Ramos Mendes Ferrari (2019)
10.1016/J.JRADIO.2013.05.007
Étude de la perfusion en sénologie
C. Bazelaire (2013)
10.5146/tjpath.2016.01366
Comparison of Microvessel Density with Prognostic Factors in Invasive Ductal Carcinomas of the Breast
E. Şener (2016)
10.3892/ol.2018.9312
Intravoxel incoherent motion magnetic resonance imaging for breast cancer: A comparison with benign lesions and evaluation of heterogeneity in different tumor regions with prognostic factors and molecular classification
M. Zhao (2018)
10.3389/fonc.2020.585486
Intravoxel Incoherent Motion Diffusion-Weighted Imaging for Quantitative Differentiation of Breast Tumors: A Meta-Analysis
J. Liang (2020)
10.1007/s13277-015-4646-x
The search for optimal cutoff points for apoptosis and proliferation rate in prognostification of early stage breast cancer patients treated with anthracyclines in adjuvant settings
B. Biesaga (2015)
10.1016/j.diii.2013.06.011
Perfusion studies in senology.
C. de Bazelaire (2013)
10.1016/j.clbc.2015.09.002
Tumor Angiogenesis in Breast Cancer: Pericytes and Maturation Does Not Correlate With Lymph Node Metastasis and Molecular Subtypes.
Shreya Shrivastav (2016)
10.1007/s00432-014-1770-8
BCL-2, topoisomerase IIα, microvessel density and prognosis of early advanced breast cancer patients after adjuvant anthracycline-based chemotherapy
B. Biesaga (2014)
10.7314/APJCP.2013.14.3.1715
Effects of differential distribution of microvessel density, possibly regulated by miR-374a, on breast cancer prognosis.
Jian-Yi Li (2013)
LYMPHANGIOGENESIS ASSESSMENT AND ITS RELATION TO TUMOUR GRADE , BREAST CANCER SUBTYPE AND EXPRESSION OF BASAL MARKERS
J. Niemiec (2012)
Circulating Tumor Cells in Breast Cancer: Correlation with Clinicopathological Parameters, Hormone Profile and MicroRNA Polymorphisms Comparison of Microvessel Density with Prognostic Factors in Invasive Ductal Carcinomas of the Breast Nasal Polyp – An Incidental Paraganglioma Pulmonary Benign Metas
Ferah Sokak (2016)
10.22034/APJCP.2017.18.12.3231
Cellular and Molecular Changes in MNU-Induced Breast Tumours Injected with PF4 or bFGF
S. Nafi (2017)
10.1016/j.acthis.2015.12.009
Cyclooxygenase-2 (COX2) and p53 protein expression are interdependent in breast cancer but not associated with clinico-pathological surrogate subtypes, tumor aggressiveness and patient survival.
Kátia Piton Serra (2016)
10.18311/ajprhc/2020/25602
Evaluation of Prognostic Factors in Triple Negative Breast Cancer Patients with Emphasis on Angiogenesis
M. Ansari (2020)
10.1016/j.patbio.2015.07.001
Chemokine C-C motif ligand 18 expression correlates with tumor malignancy in breast cancer.
J. Gao (2015)
10.2217/bmm-2019-0073
Plasma C-MYC level manifesting as an indicator in progression of breast cancer.
W. Shi (2019)
Semantic Scholar Logo Some data provided by SemanticScholar